These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 17467553

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
    Amsden GW.
    J Antimicrob Chemother; 2005 Jan; 55(1):10-21. PubMed ID: 15590715
    [Abstract] [Full Text] [Related]

  • 3. Macrolides and airway inflammation in children.
    Shinkai M, Rubin BK.
    Paediatr Respir Rev; 2005 Sep; 6(3):227-35. PubMed ID: 16153572
    [Abstract] [Full Text] [Related]

  • 4. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.
    López-Boado YS, Rubin BK.
    Curr Opin Pharmacol; 2008 Jun; 8(3):286-91. PubMed ID: 18339582
    [Abstract] [Full Text] [Related]

  • 5. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
    Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK.
    Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Role of long term antibiotics in chronic respiratory diseases.
    Suresh Babu K, Kastelik J, Morjaria JB.
    Respir Med; 2013 Jun; 107(6):800-15. PubMed ID: 23522403
    [Abstract] [Full Text] [Related]

  • 8. Rapidly progressive lung disease in a patient with cystic fibrosis on long-term azithromycin: possible role of mycoplasma infection.
    Janahi IA, Abdulwahab A, Elshafie Sittana S, Bush A.
    J Cyst Fibros; 2005 Mar; 4(1):71-3. PubMed ID: 15752685
    [Abstract] [Full Text] [Related]

  • 9. Long-term macrolide treatment for chronic respiratory disease.
    Spagnolo P, Fabbri LM, Bush A.
    Eur Respir J; 2013 Jul; 42(1):239-51. PubMed ID: 23180583
    [Abstract] [Full Text] [Related]

  • 10. Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF).
    Tazumi A, Maeda Y, Goldsmith CE, Coulter WA, Mason C, Millar BC, McCalmont M, Rendall J, Elborn JS, Matsuda M, Moore JE.
    J Antimicrob Chemother; 2009 Sep; 64(3):501-6. PubMed ID: 19584106
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Why use long-term macrolide therapy in pediatric pulmonology?].
    Corvol H, Taytard J, Thouvenin G, Périsson C, Nathan N, Clement A.
    Arch Pediatr; 2014 Mar; 21(3):314-21. PubMed ID: 24503457
    [Abstract] [Full Text] [Related]

  • 13. Azithromycin is the answer in paediatric respiratory medicine, but what was the question?
    Bush A.
    Paediatr Respir Rev; 2020 Apr; 34():67-74. PubMed ID: 31629643
    [Abstract] [Full Text] [Related]

  • 14. The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis.
    Sibley CD, Parkins MD, Rabin HR, Surette MG.
    Curr Opin Investig Drugs; 2009 Aug; 10(8):787-94. PubMed ID: 19649923
    [Abstract] [Full Text] [Related]

  • 15. Use of macrolides and tetracyclines for chronic inflammatory diseases.
    Voils SA, Evans ME, Lane MT, Schosser RH, Rapp RP.
    Ann Pharmacother; 2005 Jan; 39(1):86-94. PubMed ID: 15562139
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Azithromycin for improving pulmonary function in cystic fibrosis.
    Carr RR, Nahata MC.
    Ann Pharmacother; 2004 Sep; 38(9):1520-4. PubMed ID: 15213312
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cystic fibrosis pulmonary guidelines: airway clearance therapies.
    Flume PA, Robinson KA, O'Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, White TB, Marshall BC, Clinical Practice Guidelines for Pulmonary Therapies Committee.
    Respir Care; 2009 Apr; 54(4):522-37. PubMed ID: 19327189
    [Abstract] [Full Text] [Related]

  • 20. Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: past, present and future.
    Oermann CM.
    Curr Opin Investig Drugs; 2001 Jul; 2(7):900-6. PubMed ID: 11757788
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.